Invention Grant
- Patent Title: Liposomal gadolinium (GD) contrast agent “NMRX” for T1-MRI
-
Application No.: US16333832Application Date: 2017-09-15
-
Publication No.: US11052162B2Publication Date: 2021-07-06
- Inventor: Ananth Annapragada , Anil Shetty , Ketankumar B Ghaghada , Eric Tanifum
- Applicant: TEXAS CHILDREN'S HOSPITAL
- Applicant Address: US TX Houston
- Assignee: TEXAS CHILDREN'S HOSPITAL
- Current Assignee: TEXAS CHILDREN'S HOSPITAL
- Current Assignee Address: US TX Houston
- Agency: Norton Rose Fulbright US LLP
- International Application: PCT/IB2017/055611 WO 20170915
- International Announcement: WO2018/051289 WO 20180322
- Main IPC: A61K49/18
- IPC: A61K49/18 ; A61K49/10 ; C07F5/00

Abstract:
The present invention is directed towards new chemical entities based on a lipid-paramagnetic metal ion chelate. The lipid portion of the compound intercalates into the membrane of a liposome. The compounds of the invention find particular use as paramagnetic contrast media for magnetic resonance imaging. It has been surprisingly discovered that the liposomal contrast media do not substantially cross the placental barrier into the vasculature of the fetus(es) when administered to a pregnant subject. These novel compounds are useful in the diagnosis of disorders and diseases in both gravid and non-gravid subjects. The invention is also directed towards pharmaceutical compositions comprising these compounds and the uses of these compounds.
Public/Granted literature
- US20190255196A1 NOVEL LIPOSOMAL GADOLINIUM (GD) CONTRAST AGENT "NMRX" FOR T1-MRI Public/Granted day:2019-08-22
Information query